Participated · Series A · Jun 2026

Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.

Participated · Series B · Apr 2026

Restore Vision is developing optogenetics-based gene therapies, notably its lead program RV-001 which introduces a proprietary light-sensor protein called Chimera Rhodopsin into retinal interneurons via AAV intravitreal injection. The approach targets retinal diseases such as retinitis pigmentosa where photoreceptors have been lost. The company has completed first patient administration in a Phase I/II clinical trial of RV-001 at Keio University Hospital. Restore Vision plans to advance global clinical development of RV-001 and to pursue research and development of a second pipeline. Financially, the company has raised approximately ¥3.5 billion in equity to date and received about ¥2.1 billion in AMED grants, totaling roughly ¥5.8 billion in funding, with potential for an additional ¥4.5 billion through the AMED project.

Participated · Series B · Apr 2026

Sidewinder Therapeutics is focused on engineering next-generation bispecific ADCs that target tumor-specific receptor co-complexes to enhance tumor specificity and internalization. The company’s pipeline targets indications including squamous cell carcinomas of the lung and head and neck and gastrointestinal cancers such as colorectal cancer. Sidewinder was founded in 2023 and is headquartered in San Diego. It has partnered with Lonza to apply Synaffix’s site-specific linker‑payload platform across multiple programs. The company plans to advance its lead program into clinical development in 2027. Financially, Sidewinder has raised a total of $162 million following the $137 million Series B.

Participated · Series A · Apr 2025

Solu Therapeutics is a biotechnology company pioneering therapies that eliminate disease-driving cells across cancer, immunology, and other therapeutic areas using proprietary CyTAC and TicTAC platforms. Its lead candidate, STX-0712, is a CyTAC designed to target CCR2 and selectively eliminate CCR2-positive malignant monocytes, with an initial focus on CMML and other hematologic malignancies. The company has initiated a first-in-human, open-label, multicenter Phase 1 trial of STX-0712 with a two-part design: Part A dose escalation to determine the maximum tolerated dose and/or minimum effective dose in resistant/refractory CMML, and Part B to evaluate safety, tolerability, recommended Phase 2 dose, and preliminary antitumor activity. Solu presented preclinical ex vivo data at the 2024 ASH Annual Meeting showing robust activity of STX-0712 against CCR2-positive monocytes from CMML patient samples. Proceeds from the recent financing will be used to complete dose escalation and expansion of STX-0712, generate new development candidates including a first-in-class mast cell depletor for immunological diseases, advance additional discovery programs, and explore new applications for the CyTAC and TicTAC platforms. The company was cofounded by Longwood Fund and is based in Boston. Solu Therapeutics is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity using its proprietary CyTaC (Cytotoxicity Targeting Chimera) platform. CyTaC molecules, licensed from GSK, aim to unlock antibody-intractable cell surface targets and combine the potency of biologics with the broad target binding of small molecules. Characteristics of the platform include unlocking new tumor-associated antigens to eliminate cancer cells, depleting pathogenic immune cells, and extending the half-life of small-molecule antagonists and agonists. The company intends to use the financing to develop the proprietary CyTaC platform and associated drug candidates in-licensed from GSK. Under the license, GSK received equity in Solu and will receive milestones and royalties on products derived from the CyTaC platform. Solu is led by co-founder and CEO David Donabedian, Ph.D., and is based in Boston, MA.

Participated · Series B · Sep 2024

PhoreMost is a Cambridge, UK-based biopharmaceutical company focused on discovering novel ligases and developing degrader therapeutics using its SITESEEKER® target ID platform. The company has also launched the GlueSEEKER™ platform to inform molecular glue design for targets not previously addressable. PhoreMost expanded its drug discovery operations and advanced multiple next-generation degrader programmes through proof-of-concept studies since its prior Series B close in 2021. The new funding will enable progression of novel degrader programs in oncology and inflammatory diseases toward preclinical development. The investment will also support further deployment of GlueSEEKER and the growth of new and existing pharma collaborations. PhoreMost is led by CEO Dr Neil Torbett. PhoreMost is a Cambridge-based biopharmaceutical company whose SITESEEKER® platform identifies novel therapeutic targets and rapidly discovers ways to drug them, including novel E3 ligands relevant to targeted protein degradation. The company is advancing a preclinical 'Allosteric PLK1' programme in collaboration with Sentinel Oncology toward clinical entry in 2022, initially targeting glioma. PhoreMost intends to progress multiple additional internal first-in-class drug-discovery programmes across oncology and ageing indications. The SITESEEKER platform has been deployed to expand target diversity and generate pipeline assets across oncology, ageing and targeted protein degradation modalities. Financially, the company completed an oversubscribed £33m ($46m) Series B and previously raised £11m ($15m) in a 2018 Series A. Management also announced board changes following the round, including Dr Catherine Beech assuming the Chair with Dr Jonathan Milner remaining as a non-executive director. PhoreMost’s core product is the next‑generation SITESEEKER® phenotypic screening platform, which identifies novel and cryptic druggable sites and suggests routes to develop small‑molecule drugs against them. The company has built a proprietary target pipeline, signed two pharma collaboration deals, and spun out NeoPhore to advance a cancer immunotherapy target into small‑molecule development. Founded as a Cambridge University spin‑out in 2015, PhoreMost completed technical and commercial validation by 2017. The Series‑A funding will be used to expand operations on the Babraham Research Campus and to progress several targets from SITESEEKER into first‑in‑class drug discovery programmes. Management states the approach aims to increase the diversity and affordability of novel therapies for cancer and other unmet diseases. PhoreMost, based in Cambridge, UK, has developed a screening platform called SiteSeeker that identifies cryptic druggable sites on targets and proposes ways to rapidly drug them with novel small molecules. The company was founded by Dr Chris Torrance (CEO) and Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research at the University of Cambridge and Director of the MRC Cancer Unit. It raised £4m in Series A equity and grant funding to advance its pipeline. PhoreMost intends to use the funds to develop selective and patient-specific drugs for cancer and other conditions lacking therapeutic options. The company also plans to explore cost-effective ways to apply such treatments. Hermann Hauser of Amadeus joined PhoreMost’s board in conjunction with the financing.